HMGB1 and pulmonary arterial hypertension: An inhibitor of HMGB1–TLR4 interaction has been characterized as a novel potential therapeutic, translating the findings with the TLR4–HMGB1 pathway to a potential clinical treatment in PAH, although clinical evaluation is necessary as a next step after the initial preclinical study (151, 152).